Treatment of relapsed and refractory multiple myeloma in the era of novel agents

Cancer Treatment Reviews

Volumn 37, Issue 4, 2011, Pages 266-283

  van de Donk, Niels W C J ^a   Lokhorst, Henk M ^a   Dimopoulos, Meletios ^b   Cavo, Michele ^c   Morgan, Gareth ^d   Einsele, Hermann ^e   Kropff, Martin ^f   Schey, Steve ^g   Avet Loiseau, Hervé ^h   Ludwig, Heinz ⁱ   Goldschmidt, Hartmut ^j   Sonneveld, Pieter ^k   Johnsen, Hans E ^l   Bladé, Joan ^m   San Miguel, Jesús F ⁿ   Palumbo, Antonio ^o  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^e UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^f UNIVERSITY OF MÜNSTER   (Germany)

^g KING S COLLEGE HOSPITAL   (United Kingdom)

^h NANTES UNIVERSITY HOSPITAL   (France)

ⁱ Wilhelminenspital ^*  (Austria)

^j UNIVERSITY OF HEIDELBERG   (Germany)

^k ERASMUS MEDICAL CENTER   (Netherlands)

^l AALBORG UNIVERSITY HOSPITAL   (Denmark)

^m HOSPITAL CLÍNIC   (Spain)

ⁿ HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^o UNIVERSITY OF TURIN   (Italy)

more..

Author keywords

Bortezomib; Guidelines; Lenalidomide; Multiple myeloma; Novel agents; Refractory disease; Relapse treatment; Thalidomide

Indexed keywords

BENDAMUSTINE; BORTEZOMIB; CARFILZOMIB; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACETUZUMAB; DEXAMETHASONE; DOXORUBICIN; ELOTUZUMAB; ETOPOSIDE; EVEROLIMUS; LENALIDOMIDE; MELPHALAN; PANOBINOSTAT; PERIFOSINE; POMALIDOMIDE; PREDNISONE; ROMIDEPSIN; SALINOSPORAMIDE A; SILTUXIMAB; TANESPIMYCIN; TEMSIROLIMUS; THALIDOMIDE; VINCRISTINE; VORINOSTAT;

ALLOGENEIC STEM CELL TRANSPLANTATION; ANEMIA; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BRADYCARDIA; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); CONSTIPATION; DIARRHEA; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; FATIGUE; GASTROINTESTINAL SYMPTOM; HERPES ZOSTER; HUMAN; INFECTION; LOW DRUG DOSE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUROPATHY; NEUTROPENIA; PERIPHERAL NEUROPATHY; RASH; REVIEW; SENSORY NEUROPATHY; SKIN MANIFESTATION; SOMNOLENCE; SURVIVAL TIME; THROMBOCYTOPENIA; VENOUS THROMBOEMBOLISM;

ANTINEOPLASTIC AGENTS; HUMANS; IMMUNOLOGIC FACTORS; MULTIPLE MYELOMA; NEOPLASM RECURRENCE, LOCAL; PROTEASOME ENDOPEPTIDASE COMPLEX; TREATMENT OUTCOME;

EID: 79953125606     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2010.08.008     Document Type: Review

References (225)

1. Kumar S.K., Rajkumar S.V., Dispenzieri A., Lacy M.Q., Hayman S.R., Buadi F.K., et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008, 111(5):2516-2520.
2. Durie B.G., Harousseau J.L., Miguel J.S., Blade J., Barlogie B., Anderson K., et al. International uniform response criteria for multiple myeloma. Leukemia 2006, 20(9):1467-1473.
3. Anderson K.C., Kyle R.A., Rajkumar S.V., Stewart A.K., Weber D., Richardson P. Clinically relevant end points and new drug approvals for myeloma. Leukemia 2008, 22(2):231-239.
4. The International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003;121(5):749-57.
5. Singhal S., Mehta J., Desikan R., Ayers D., Roberson P., Eddlemon P., et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999, 341(21):1565-1571.
6. Barlogie B., Desikan R., Eddlemon P., Spencer T., Zeldis J., Munshi N., et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 2001, 98(2):492-494.
7. Tosi P., Zamagni E., Cellini C., Ronconi S., Patriarca F., Ballerini F., et al. Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma. Haematologica 2002, 87(4):408-414.
8. Yakoub-Agha I., Attal M., Dumontet C., Delannoy V., Moreau P., Berthou C., et al. Thalidomide in patients with advanced multiple myeloma: a study of 83 patients - report of the Intergroupe Francophone du Myelome (IFM). Hematol J 2002, 3(4):185-192.
9. Juliusson G., Celsing F., Turesson I., Lenhoff S., Adriansson M., Malm C. Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma. Br J Haematol 2000, 109(1):89-96.
10. Richardson P., Schlossman R., Jagannath S., Alsina M., Desikan R., Blood E., et al. Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity. Mayo Clin Proc 2004, 79(7):875-882.
11. Hus M., Dmoszynska A., Soroka-Wojtaszko M., Jawniak D., Legiec W., Ciepnuch H., et al. Thalidomide treatment of resistant or relapsed multiple myeloma patients. Haematologica 2001, 86(4):404-408.
12. Wu K.L., Helgason H.H., van der H.B., Wijermans P.W., Lokhorst H.M., Smit W.M., et al. Analysis of efficacy and toxicity of thalidomide in 122 patients with multiple myeloma: response of soft-tissue plasmacytomas. Leukemia 2005, 19(1):143-145.
13. Mileshkin L., Biagi J.J., Mitchell P., Underhill C., Grigg A., Bell R., et al. Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age. Blood 2003, 102(1):69-77.
14. Waage A., Gimsing P., Juliusson G., Turesson I., Gulbrandsen N., Eriksson T., et al. Early response predicts thalidomide efficiency in patients with advanced multiple myeloma. Br J Haematol 2004, 125(2):149-155.
15. Kropff M., Baylon H.G., Hillengass J., Robak T., Hajek R., Liebisch P., et al. Optimum dose of thalidomide for relapsed multiple myeloma. ASH Annu Meeting Abstr 2009, 114(22):959.
16. Neben K., Moehler T., Benner A., Kraemer A., Egerer G., Ho A.D., et al. Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma. Clin Cancer Res 2002, 8(11):3377-3382.
17. Palumbo A., Rajkumar S.V., Dimopoulos M.A., Richardson P.G., San M.J., Barlogie B., et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 2008, 22(2):414-423.
18. Hideshima T., Chauhan D., Shima Y., Raje N., Davies F.E., Tai Y.T., et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000, 96(9):2943-2950.
19. Palumbo A., Giaccone L., Bertola A., Pregno P., Bringhen S., Rus C., et al. Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma. Haematologica 2001, 86(4):399-403.
20. Anagnostopoulos A., Weber D., Rankin K., Delasalle K., Alexanian R. Thalidomide and dexamethasone for resistant multiple myeloma. Br J Haematol 2003, 121(5):768-771.
21. Palumbo A., Bertola A., Falco P., Rosato R., Cavallo F., Giaccone L., et al. Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma. Hematol J 2004, 5(4):318-324.
22. Alexanian R., Weber D., Anagnostopoulos A., Delasalle K., Wang M., Rankin K. Thalidomide with or without dexamethasone for refractory or relapsing multiple myeloma. Semin Hematol 2003, 40(4 Suppl 4):3-7.
23. Dimopoulos M.A., Zervas K., Kouvatseas G., Galani E., Grigoraki V., Kiamouris C., et al. Thalidomide and dexamethasone combination for refractory multiple myeloma. Ann Oncol 2001, 12(7):991-995.
24. Kropff M.H., Lang N., Bisping G., Domine N., Innig G., Hentrich M., et al. Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (hyperCDT) in primary refractory or relapsed multiple myeloma. Br J Haematol 2003, 122(4):607-616.
25. Dimopoulos M.A., Hamilos G., Zomas A., Gika D., Efstathiou E., Grigoraki V., et al. Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma. Hematol J 2004, 5(2):112-117.
26. Sidra G., Williams C.D., Russell N.H., Zaman S., Myers B., Byrne J.L. Combination chemotherapy with cyclophosphamide, thalidomide and dexamethasone for patients with refractory, newly diagnosed or relapsed myeloma. Haematologica 2006, 91(6):862-863.
27. Kyriakou C., Thomson K., D'Sa S., Flory A., Hanslip J., Goldstone A.H., et al. Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma. Br J Haematol 2005, 129(6):763-770.
28. Garcia-Sanz R., Gonzalez-Porras J.R., Hernandez J.M., Polo-Zarzuela M., Sureda A., Barrenetxea C., et al. The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma. Leukemia 2004, 18(4):856-863.
29. Celesti L., Clavio M., Poggi A., Casciaro S., Vallebella E., Gobbi M. The association of cyclophosphamide and dexamethasone in advanced refractory multiple myeloma patients. Haematologica 1997, 82(3):351-353.
30. Brandes L.J., Israels L.G. Weekly low-dose cyclophosphamide and alternate-day prednisone: an effective low toxicity regimen for advanced myeloma. Eur J Haematol 1987, 39(4):362-368.
31. de Weerdt O., van de Donk N.W., Veth G., Bloem A.C., Hagenbeek A., Lokhorst H.M. Continuous low-dose cyclophosphamide-prednisone is effective and well tolerated in patients with advanced multiple myeloma. Neth J Med 2001, 59(2):50-56.
32. Trieu Y., Trudel S., Pond G.R., Mikhael J., Jaksic W., Reece D.E., et al. Weekly cyclophosphamide and alternate-day prednisone: an effective, convenient, and well-tolerated oral treatment for relapsed multiple myeloma after autologous stem cell transplantation. Mayo Clin Proc 2005, 80(12):1578-1582.
33. Hovenga S., Daenen S.M., de Wolf J.T., van Imhoff G.W., Kluin-Nelemans H.C., Sluiter W.J., et al. Combined thalidomide and cyclophosphamide treatment for refractory or relapsed multiple myeloma patients: a prospective phase II study. Ann Hematol 2005, 84(5):311-316.
34. Offidani M., Marconi M., Corvatta L., Olivieri A., Catarini M., Leoni P. Thalidomide plus oral melphalan for advanced multiple myeloma: a phase II study. Haematologica 2003, 88(12):1432-1433.
35. Palumbo A., Avonto I., Bruno B., Ambrosini M.T., Bringhen S., Cavallo F., et al. Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma. Eur J Haematol 2006, 76(4):273-277.
36. Srkalovic G., Elson P., Trebisky B., Karam M.A., Hussein M.A. Use of melphalan, thalidomide, and dexamethasone in treatment of refractory and relapsed multiple myeloma. Med Oncol 2002, 19(4):219-226.
37. Offidani M., Corvatta L., Marconi M., Visani G., Alesiani F., Brunori M., et al. Low-dose thalidomide with pegylated liposomal doxorubicin and high-dose dexamethasone for relapsed/refractory multiple myeloma: a prospective, multicenter, phase II study. Haematologica 2006, 91(1):133-136.
38. Hussein M.A., Baz R., Srkalovic G., Agrawal N., Suppiah R., Hsi E., et al. Phase 2 study of pegylated liposomal doxorubicin, vincristine, decreased-frequency dexamethasone, and thalidomide in newly diagnosed and relapsed-refractory multiple myeloma. Mayo Clin Proc 2006, 81(7):889-895.
39. Lee C.K., Barlogie B., Munshi N., Zangari M., Fassas A., Jacobson J., et al. DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. J Clin Oncol 2003, 21(14):2732-2739.
40. Moehler T.M., Neben K., Benner A., Egerer G., Krasniqi F., Ho A.D., et al. Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy. Blood 2001, 98(13):3846-3848.
41. Ponisch W., Rozanski M., Goldschmidt H., Hoffmann F.A., Boldt T., Schwarzer A., et al. Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a Phase I clinical trial. Br J Haematol 2008, 143(2):191-200.
42. Knop S., Straka C., Haen M., Schwedes R., Hebart H., Einsele H. The efficacy and toxicity of bendamustine in recurrent multiple myeloma after high-dose chemotherapy. Haematologica 2005, 90(9):1287-1288.
43. Michael M., Bruns I., Bolke E., Zohren F., Czibere A., Safaian N.N., et al. Bendamustine in patients with relapsed or refractory multiple myeloma. Eur J Med Res 2010, 15(1):13-19.
44. Ponisch W., Mitrou P.S., Merkle K., Herold M., Assmann M., Wilhelm G., et al. Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone - a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO). J Cancer Res Clin Oncol 2006, 132(4):205-212.
45. Muller G.W., Chen R., Huang S.Y., Corral L.G., Wong L.M., Patterson R.T., et al. Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production. Bioorg Med Chem Lett 1999, 9(11):1625-1630.
46. Corral L.G., Haslett P.A., Muller G.W., Chen R., Wong L.M., Ocampo C.J., et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol 1999, 163(1):380-386.
47. List A.F. Lenalidomide - the phoenix rises. N Engl J Med 2007, 357(21):2183-2186.
48. Richardson P.G., Schlossman R.L., Weller E., Hideshima T., Mitsiades C., Davies F., et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002, 100(9):3063-3067.
49. Richardson P.G., Blood E., Mitsiades C.S., Jagannath S., Zeldenrust S.R., Alsina M., et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 2006, 108(10):3458-3464.
50. Richardson P., Jagannath S., Hussein M., Berenson J., Singhal S., Irwin D., et al. Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma. Blood 2009, 114(4):772-778.
51. Mitsiades N., Mitsiades C.S., Poulaki V., Chauhan D., Richardson P.G., Hideshima T., et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 2002, 99(12):4525-4530.
52. Weber D.M., Chen C., Niesvizky R., Wang M., Belch A., Stadtmauer E.A., et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007, 357(21):2133-2142.
53. Dimopoulos M., Spencer A., Attal M., Prince H.M., Harousseau J.L., Dmoszynska A., et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007, 357(21):2123-2132.
54. Dimopoulos M.A., Chen C., Spencer A., Niesvizky R., Attal M., Stadtmauer E.A., et al. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia 2009, 23(11):2147-2152.
55. Knop S., Gerecke C., Liebisch P., Topp M.S., Platzbecker U., Sezer O., et al. Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche studiengruppe multiples myelom). Blood 2009, 113(18):4137-4143.
56. van de Donk N.W., Wittebol S., Minnema M.C., Lokhorst H.M. Lenalidomide (Revlimid) combined with continuous oral cyclophosphamide (endoxan) and prednisone (REP) is effective in lenalidomide/dexamethasone-refractory myeloma. Br J Haematol 2010, 148(2):335-337.
57. Morgan G.J., Schey S.A., Wu P., Srikanth M., Phekoo K.J., Jenner M., et al. Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients. Br J Haematol 2007, 137(3):268-269.
58. Reece D.E., Masih-Khan E., Khan A., Dean S., Anglin P., Chen C., et al. Phase I-II trial of oral cyclophosphamide, prednisone and lenalidomide (revlimid(R)) (CPR) for the treatment of patients with relapsed and refractory multiple myeloma. ASH Annu Meeting Abstr 2009, 114(22):1874.
59. Schey S., Morgan G.J., Ramasamy K., Hazel B., Phekoo K., Corderoy S., et al. CRD: a phase 1 dose escalation study to determine the maximum tolerated dose of cyclophosphamide in combination with lenalidomide and dexamethasone in relapsed/refractory myeloma. ASH Annu Meeting Abstr 2008, 112(11):3707.
60. Baz R., Walker E., Karam M.A., Choueiri T.K., Jawde R.A., Bruening K., et al. Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy. Ann Oncol 2006, 17(12):1766-1771.
61. Lentzsch S., O'Sullivan A., Lalo S., Kruppa C., Gardner D., Kennedy R.C., et al. A phase I study of bendamustine combined with lenalidomide and dexamethasone in patients with refractory or relapsed multiple myeloma. ASH Annu Meeting Abstr 2009, 114(22):1856.
62. Schey S.A., Fields P., Bartlett J.B., Clarke I.A., Ashan G., Knight R.D., et al. Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J Clin Oncol 2004, 22(16):3269-3276.
63. Streetly M.J., Gyertson K., Daniel Y., Zeldis J.B., Kazmi M., Schey S.A. Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation. Br J Haematol 2008, 141(1):41-51.
64. Lacy M.Q., Hayman S.R., Gertz M.A., Dispenzieri A., Buadi F., Kumar S., et al. Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol 2009, 27(30):5008-5014.
65. Orlowski R.Z., Stinchcombe T.E., Mitchell B.S., Shea T.C., Baldwin A.S., Stahl S., et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 2002, 20(22):4420-4427.
66. Richardson P.G., Barlogie B., Berenson J., Singhal S., Jagannath S., Irwin D., et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003, 348(26):2609-2617.
67. Jagannath S., Barlogie B., Berenson J., Siegel D., Irwin D., Richardson P.G., et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004, 127(2):165-172.
68. Richardson P.G., Sonneveld P., Schuster M.W., Irwin D., Stadtmauer E.A., Facon T., et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005, 352(24):2487-2498.
69. Richardson P.G., Sonneveld P., Schuster M., Irwin D., Stadtmauer E., Facon T., et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood 2007, 110(10):3557-3560.
70. Lee S.J., Richardson P.G., Sonneveld P., Schuster M.W., Irwin D., San Miguel J.F., et al. Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study. Br J Haematol 2008, 143(4):511-519.
71. Nucci M., Anaissie E. Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents. Clin Infect Dis 2009, 49(8):1211-1225.
72. Lonial S., Richardson P.G., San M.J., Sonneveld P., Schuster M.W., Blade J., et al. Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma. Br J Haematol 2008, 143(2):222-229.
73. Hideshima T., Chauhan D., Richardson P., Mitsiades C., Mitsiades N., Hayashi T., et al. NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem 2002, 277(19):16639-16647.
74. Hideshima T., Richardson P., Chauhan D., Palombella V.J., Elliott P.J., Adams J., et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001, 61(7):3071-3076.
75. Mitsiades N., Mitsiades C.S., Richardson P.G., Poulaki V., Tai Y.T., Chauhan D., et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2003, 101(6):2377-2380.
76. Ma M.H., Yang H.H., Parker K., Manyak S., Friedman J.M., Altamirano C., et al. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res 2003, 9(3):1136-1144.
77. Kropff M.H., Bisping G., Wenning D., Volpert S., Tchinda J., Berdel W.E., et al. Bortezomib in combination with dexamethasone for relapsed multiple myeloma. Leuk Res 2005, 29(5):587-590.
78. Jagannath S., Richardson P.G., Barlogie B., Berenson J.R., Singhal S., Irwin D., et al. Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. Haematologica 2006, 91(7):929-934.
79. Mikhael J.R., Belch A.R., Prince H.M., Lucio M.N., Maiolino A., Corso A., et al. High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program. Br J Haematol 2009, 144(2):169-175.
80. Orlowski R.Z., Voorhees P.M., Garcia R.A., Hall M.D., Kudrik F.J., Allred T., et al. Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood 2005, 105(8):3058-3065.
81. Orlowski R.Z., Nagler A., Sonneveld P., Blade J., Hajek R., Spencer A., et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol 2007, 25(25):3892-3901.
82. Palumbo A., Gay F., Bringhen S., Falcone A., Pescosta N., Callea V., et al. Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma. Ann Oncol 2008, 19(6):1160-1165.
83. Berenson J.R., Yang H.H., Sadler K., Jarutirasarn S.G., Vescio R.A., Mapes R., et al. Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. J Clin Oncol 2006, 24(6):937-944.
84. Popat R., Oakervee H., Williams C., Cook M., Craddock C., Basu S., et al. Bortezomib, low-dose intravenous melphalan, and dexamethasone for patients with relapsed multiple myeloma. Br J Haematol 2009, 144(6):887-894.
85. Fenk R., Michael M., Zohren F., Graef T., Czibere A., Bruns I., et al. Escalation therapy with bortezomib, dexamethasone and bendamustine for patients with relapsed or refractory multiple myeloma. Leuk Lymphoma 2007, 48(12):2345-2351.
86. Reece D.E., Rodriguez G.P., Chen C., Trudel S., Kukreti V., Mikhael J., et al. Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma. J Clin Oncol 2008, 26(29):4777-4783.
87. Davies F.E., Wu P., Jenner M., Srikanth M., Saso R., Morgan G.J. The combination of cyclophosphamide, velcade and dexamethasone induces high response rates with comparable toxicity to velcade alone and velcade plus dexamethasone. Haematologica 2007, 92(8):1149-1150.
88. Kropff M., Bisping G., Schuck E., Liebisch P., Lang N., Hentrich M., et al. Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma. Br J Haematol 2007, 138(3):330-337.
89. Kuhn D.J., Chen Q., Voorhees P.M., Strader J.S., Shenk K.D., Sun C.M., et al. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood 2007, 110(9):3281-3290.
90. Wang L., Siegel D., Kaufman J.L., Stewart A.K., Jakubowiak A.J., Alsina M., et al. Updated results of bortezomib-naive patients in PX-171-004, an ongoing open-label, phase ii study of single-agent carfilzomib (CFZ) in patients with relapsed or refractory myeloma (MM). ASH Annu Meeting Abstr 2009, 114(22):302.
91. Siegel D., Wang L., Orlowski R.Z., Kaufman J.L., Stewart A.K., Kukreti V., et al. PX-171-004, an ongoing open-label, phase ii study of single-agent carfilzomib (CFZ) in patients with relapsed or refractory myeloma (MM); updated results from the bortezomib-treated cohort. ASH Annu Meeting Abstr 2009, 114(22):303.
92. Jakubowiak A., Wang L., Orlowski R.Z., Jagannath S., Siegel D., Stewart A.K., et al. Influence of cytogenetics in patients with relapsed and refractory multiple myeloma (MM) treated with carfilzomib (CFZ). ASH Annu Meeting Abstr 2009, 114(22):1827.
93. Chauhan D., Catley L., Li G., Podar K., Hideshima T., Velankar M., et al. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from bortezomib. Cancer Cell 2005, 8(5):407-419.
94. Spencer A., Millward M., Mainwaring P., Harrison S., Catley L., Townsend A., et al. Phase 1 clinical trial of the novel structure proteasome inhibitor NPI-0052. ASH Annu Meeting Abstr 2009, 114(22):2693.
95. Richardson P., Hofmeister C., Jakubowiak A., Zimmerman T.M., Spear M.A., Palladino M.A., et al. Phase 1 clinical trial of the novel structure proteasome inhibitor NPI-0052 in patients with relapsed and relapsed/refractory multiple myeloma (MM). ASH Annu Meeting Abstr 2009, 114(22):431.
96. Pineda-Roman M., Zangari M., van R.F., Anaissie E., Szymonifka J., Hoering A., et al. VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma. Leukemia 2008, 22(7):1419-1427.
97. Ciolli S., Leoni F., Gigli F., Rigacci L., Bosi A. Low dose velcade, thalidomide and dexamethasone (LD-VTD): an effective regimen for relapsed and refractory multiple myeloma patients. Leuk Lymphoma 2006, 47(1):171-173.
98. Ciolli S., Leoni F., Casini C., Breschi C., Santini V., Bosi A. The addition of liposomal doxorubicin to bortezomib, thalidomide and dexamethasone significantly improves clinical outcome of advanced multiple myeloma. Br J Haematol 2008, 141(6):814-819.
99. Chanan-Khan A., Miller K.C., Musial L., Padmanabhan S., Yu J., Ailawadhi S., et al. Bortezomib in combination with pegylated liposomal doxorubicin and thalidomide is an effective steroid independent salvage regimen for patients with relapsed or refractory multiple myeloma: results of a phase II clinical trial. Leuk Lymphoma 2009, 50(7):1096-1101.
100. Kim Y.K., Sohn S.K., Lee J.H., Yang D.H., Moon J.H., Ahn J.S., et al. Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: a phase II study. Ann Hematol 2010, 89(5):475-482.
101. Palumbo A., Falco P., Corradini P., Falcone A., Di R.F., Giuliani N., et al. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA - Italian Multiple Myeloma Network. J Clin Oncol 2007, 25(28):4459-4465.
102. Facon T., Mary J.Y., Hulin C., Benboubker L., Attal M., Pegourie B., et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 2007, 370(9594):1209-1218.
103. Palumbo A., Bringhen S., Caravita T., Merla E., Capparella V., Callea V., et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 2006, 367(9513):825-831.
104. San Miguel J.F., Schlag R., Khuageva N.K., Dimopoulos M.A., Shpilberg O., Kropff M., et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008, 359(9):906-917.
105. Palumbo A., Ambrosini M.T., Benevolo G., Pregno P., Pescosta N., Callea V., et al. Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma. Blood 2007, 109(7):2767-2772.
106. Terpos E., Kastritis E., Roussou M., Heath D., Christoulas D., Anagnostopoulos N., et al. The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis. Leukemia 2008, 22(12):2247-2256.
107. Colado E., Mateos M.V., Moreno M.J., deArriba F., de la Rubia J., Lahuerta J.J., et al. VAMP/ThaCyDex: velcade(R) (bortezomib), adriamycin, melphalan and prednisone alternating with thalidomide, cyclophosphamide and dexametasone as a salvage regimen in relapsed multiple myeloma patients. ASH Annu Meeting Abstr 2008, 112(11):3694.
108. Richardson P.G., Weller E., Jagannath S., Avigan D.E., Alsina M., Schlossman R.L., et al. Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma. J Clin Oncol 2009, 27(34):5713-5719.
109. Richardson P., Jagannath S., Jakubowiak A., Lonial S., Raje N., Alsina M., et al. Lenalidomide, bortezomib, and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (MM): encouraging response rates and tolerability with correlation of outcome and adverse cytogenetics in a phase II study. ASH Annu Meeting Abstr 2008, 112(11):1742.
110. Terpos E., Christoulas D., Kastritis E., Roussou M., Gavriatopoulou M., Migkou M., et al. The addition of bortezomib to the combination of lenalidomide and dexamethasone increases bone formation in relapsed/refractory myeloma: a prospective study in 91 patients. ASH Annu Meeting Abstr 2009, 114(22):1815.
111. Niesvizky R., Wang L., Orlowski R.Z., Bensinger W., Alsina M., Gabrail N., et al. Phase Ib multicenter dose escalation study of carfilzomib plus lenalidomide and low dose dexamethasone (CRd) in relapsed and refractory multiple myeloma (MM). ASH Annu Meeting Abstr 2009, 114(22):304.
112. Cavallo F., Larocca A., Petrucci M.T., Federico V., Falcone A.P., Sanpaolo G., et al. A prospective randomized phase i/ii study of lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myeloma patients. ASH Annu Meeting Abstr 2009, 114(22):2864.
113. Vesole D.H., Crowley J.J., Catchatourian R., Stiff P.J., Johnson D.B., Cromer J., et al. High-dose melphalan with autotransplantation for refractory multiple myeloma: results of a Southwest Oncology Group phase II trial. J Clin Oncol 1999, 17(7):2173-2179.
114. Gertz M.A., Lacy M.Q., Inwards D.J., Gastineau D.A., Tefferi A., Chen M.G., et al. Delayed stem cell transplantation for the management of relapsed or refractory multiple myeloma. Bone Marrow Transplant 2000, 26(1):45-50.
115. Fermand J.P., Ravaud P., Chevret S., Divine M., Leblond V., Belanger C., et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood 1998, 92(9):3131-3136.
116. Mansi J.L., Cunningham D., Viner C., Ellis E., Meldrum M., Milan S., et al. Repeat administration of high dose melphalan in relapsed myeloma. Br J Cancer 1993, 68(5):983-987.
117. Mikhael J.R., Zadeh S., Stewart A.K., Chen C., Trudel S., Kukreti V., et al. Second autologous stem cell transplant (ASCT) as salvage therapy in patients with relapsed multiple myeloma. ASH Annu Meeting Abstr 2009, 114(22):1217.
118. Fenk R., Liese V., Bruns I., Kondakci M., Balleisen S., Saure C., et al. Reapplication of high-dose chemotherapy and autologous blood stem cell transplantation as salvage treatment for patients with relapsed or refractory multiple myeloma - a single center experience. ASH Annu Meeting Abstr 2009, 114(22):3418.
119. Chaidos A., Giles C., Auner H.W., Bua M., Pavlu J., Smith E., et al. Second autologous stem cell transplantation is effective salvage therapy for relapsed multiple myeloma. ASH Annu Meeting Abstr 2009, 114(22):1229.
120. Lee C.K., Barlogie B., Zangari M., Fassas A., Anaissie E., Morris C., et al. Transplantation as salvage therapy for high-risk patients with myeloma in relapse. Bone Marrow Transplant 2002, 30(12):873-878.
121. Kroger N., Sayer H.G., Schwerdtfeger R., Kiehl M., Nagler A., Renges H., et al. Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality. Blood 2002, 100(12):3919-3924.
122. Giralt S., Aleman A., Anagnostopoulos A., Weber D., Khouri I., Anderlini P., et al. Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma. Bone Marrow Transplant 2002, 30(6):367-373.
123. Badros A., Barlogie B., Morris C., Desikan R., Martin S.R., Munshi N., et al. High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions. Blood 2001, 97(9):2574-2579.
124. Badros A., Barlogie B., Siegel E., Cottler-Fox M., Zangari M., Fassas A., et al. Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning. J Clin Oncol 2002, 20(5):1295-1303.
125. Maloney D.G., Molina A.J., Sahebi F., Stockerl-Goldstein K.E., Sandmaier B.M., Bensinger W., et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 2003, 102(9):3447-3454.
126. Kroger N., Schwerdtfeger R., Kiehl M., Sayer H.G., Renges H., Zabelina T., et al. Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. Blood 2002, 100(3):755-760.
127. de L.H., El-Cheikh J., Faucher C., Furst S., Stoppa A.M., Coso D., et al. Reduced-intensity conditioning allogeneic SCT as salvage treatment for relapsed multiple myeloma. Bone Marrow Transplant 2008, 41(11):953-960.
128. Crawley C., Lalancette M., Szydlo R., Gilleece M., Peggs K., Mackinnon S., et al. Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the chronic leukaemia working party of the EBMT. Blood 2005, 105(11):4532-4539.
129. Badros A.Z., Richardson P.G., Albitar M., Jagannath S., Tarantolo S., Wolf J.L., et al. Tanespimycin+bortezomib in relapsed/refractory myeloma patients: results from the time-2 study. ASH Annu Meeting Abstr 2009, 114(22):1871.
130. Richardson P.G., Chanan-Khan A.A., Lonial S., Krishnan A.Y., Carroll M.P., Albitar M., et al. Tanespimycin+bortezomib demonstrates safety, activity, and effective target inhibition in relapsed/refractory myeloma patients: updated results of a phase 1/2 study. ASH Annu Meeting Abstr 2009, 114(22):2890.
131. Richardson P., Mitsiades C., Colson K., Reilly E., McBride L., Chiao J., et al. Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma. Leuk Lymphoma 2008, 49(3):502-507.
132. Weber D., Badros A.Z., Jagannath S., Siegel D., Richon V., Rizvi S., et al. Vorinostat plus bortezomib for the treatment of relapsed/refractory multiple myeloma: early clinical experience. ASH Annu Meeting Abstr 2008, 112(11):871.
133. Badros A., Burger A.M., Philip S., Niesvizky R., Kolla S.S., Goloubeva O., et al. Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma. Clin Cancer Res 2009, 15(16):5250-5257.
134. Voorhees P.M., Gasparetto C., Richards K.L., Garcia R., Strader J.S., Ferraro M., et al. Vorinostat in combination with pegylated liposomal doxorubicin and bortezomib for patients with relapsed/refractory multiple myeloma: results of a phase i study. ASH Annu Meeting Abstr 2009, 114(22):306.
135. Siegel D., Weber D.M., Mitsiades C.S., Dimopoulos M.A., Harousseau J.L., Rizvi S., et al. Combined vorinostat, lenalidomide and dexamethasone therapy in patients with relapsed or refractory multiple myeloma: a phase i study. ASH Annu Meeting Abstr 2009, 114(22):305.
136. Wolf J.L., Siegel D., Matous J., Lonial S., Goldschmidt H., Schmitt S., et al. A phase II study of oral panobinostat (LBH589) in adult patients with advanced refractory multiple myeloma. ASH Annu Meeting Abstr 2008, 112(11):2774.
137. SanMiguel J.F., Sezer O., Siegel D., Guenther A., Mateos M.V., Prosser I., et al. Relapsed multiple myeloma. ASH Annu Meeting Abstr 2009, 114(22):3852.
138. Harrison S.J., Quach H., Yuen K., Strayer A., Copeman M.C., Peinert S., et al. High response rates with the combination of bortezomib, dexamethasone and the pan-histone deacetylase inhibitor romidepsin in patients with relapsed or refractory multiple myeloma in a phase I/II clinical trial. ASH Annu Meeting Abstr 2008, 112(11):3698.
139. Richardson P., Lonial S., Jakubowiak A., Krishnan A., Wolf J., Densmore J., et al. Multi-center phase II study of perifosine (KRX-0401) alone and in combination with dexamethasone (dex) for patients with relapsed or relapsed/refractory multiple myeloma (MM): promising activity as combination therapy with manageable toxicity. ASH Annu Meeting Abstr 2007, 110(11):1164.
140. Richardson P., Wolf J.L., Jakubowiak A., Zonder J.A., Lonial S., Irwin D.H., et al. Perifosine in combination with bortezomib and dexamethasone extends progression-free survival and overall survival in relapsed/refractory multiple myeloma patients previously treated with bortezombib: updated phase I/II trial results. ASH Annu Meeting Abstr 2009, 114(22):1869.
141. Jakubowiak A., Richardson P., Zimmerman T.M., Alsina M., Kaufman J.L., Harvey C., et al. Phase I results of perifosine (KRX-0401) in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (MM). ASH Annu Meeting Abstr 2008, 112(11):3691.
142. Farag S.S., Zhang S., Jansak B.S., Wang X., Kraut E., Chan K., et al. Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma. Leuk Res 2009, 33(11):1475-1480.
143. Guenther A., Baumann P., Burger R., Klapper W., Schmidmaier R., Gramatzki M. Phase I/II study with single agent everolimus (RAD001) in patients with relapsed or refractory multiple myeloma. ASH Annu Meeting Abstr 2009, 114(22):3850.
144. Ghobrial I.M., Vij R., Munshi N.C., Schlossman R.L., Laubach J., Campagnaro E.L., et al. Phase II trial of weekly bortezomib in combination with CCI-779 (temsirolimus) in relapsed or relapsed/refractory multiple myeloma. ASH Annu Meeting Abstr 2009, 114(22):748.
145. Raje N., Richardson P., Hari P.N., Mahindra A., Kaster S., Connolly C., et al. An open-label phase I study of the safety and efficacy of RAD001 in combination with lenalidomide in the treatment of patients with relapsed and relapsed/refractory multiple myeloma. ASH Annu Meeting Abstr 2009, 114(22):3856.
146. Tai Y.T., Dillon M., Song W., Leiba M., Li X.F., Burger P., et al. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood 2008, 112(4):1329-1337.
147. Jakubowiak A.J., Bensinger W., Siegel D., Zimmerman T.M., Van Tornout J.M., Zhao C., et al. Phase 1/2 study of elotuzumab in combination with bortezomib in patients with multiple myeloma with one to three prior therapies: interim results. ASH Annu Meeting Abstr 2009, 114(22):3876.
148. Lonial S., Vij R., Harousseau J.L., Facon T., Kaufman J., Mazumder A., et al. Phase 1/2 study of elotuzumab in combination with lenalidomide and low dose dexamethasone in relapsed or refractory multiple myeloma: interim results. ASH Annu Meeting Abstr 2009, 114(22):432.
149. Rossi J.F., Manges R.F., Sutherland H.J., Jagannath S., Voorhees P., Sonneveld P., et al. Preliminary results of CNTO 328, an anti-interleukin-6 monoclonal antibody, in combination with bortezomib in the treatment of relapsed or refractory multiple myeloma. ASH Annu Meeting Abstr 2008, 112(11):867.
150. Chanan-Khan A.A., Jagannath S., Heffner L.T., Avigan D., Lee K.P., Lutz R.J., et al. Phase I study of BT062 given as repeated single dose once every 3 weeks in patients with relapsed or relapsed/refractory multiple myeloma. ASH Annu Meeting Abstr 2009, 114(22):1862.
151. Chanan-Khan A., Wolf J., Gharibo M., Jagannath S., Munshi N.C., Anderson K.C., et al. Phase I study of IMGN901, used as monotherapy, in patients with heavily pre-treated CD56-positive multiple myeloma - a preliminary safety and efficacy analysis. ASH Annu Meeting Abstr 2009, 114(22):2883.
152. Hussein M., Berenson J.R., Niesvizky R., Munshi N., Matous J., Sobecks R., et al. A phase 1 multidose study of dacetuzumab (SGN-40; humanized anti-CD40 mAb) in patients with multiple myeloma. Haematologica 2010, 95(5):845-848.
153. Vogl D.T., Stadtmauer E.A., Richardson P.G., Sonneveld P., Schuster M.W., Irwin D., et al. Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma. Br J Haematol 2009, 147(4):531-534.
154. Sonneveld P., Hajek R., Nagler A., Spencer A., Blade J., Robak T., et al. Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy. Cancer 2008, 112(7):1529-1537.
155. Wang M., Dimopoulos M.A., Chen C., Cibeira M.T., Attal M., Spencer A., et al. Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure. Blood 2008, 112(12):4445-4451.
156. Avet-Loiseau H., Soulier J., Fermand J.P., Yakoub-Agha I., Attal M., Hulin C., et al. Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone. Leukemia 2010, 24(3):623-628.
157. Dimopoulos M.A., Christoulas D., Roussou M., Kastritis E., Migkou M., Gavriatopoulou M., et al. Lenalidomide and dexamethasone for the treatment of refractory/relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairment. Eur J Haematol 2010, 85(1):1-5.
158. Kneppers E., Lokhorst H.M., Eeltink C.M., Huls G., Kersten M.J., Koedam J., et al. Analysis of efficacy and prognostic factors of lenalidomide treatment as part of a Dutch compassionate use program. Clin Lymphoma Myeloma Leuk 2010, 10(2):138-143.
159. Reece D.E., Trieu Y., Chen C., Kukreti V., Xu W., Anglin P., et al. Sequencing novel agents in relapsed/refractory multiple myeloma: use of bortezomib-based therapy after lenalidomide+dexamethasone. ASH Annu Meeting Abstr 2009, 114(22):1853.
160. Young T., Chu C.M., Xu W., Anglin P., Trudel S., Reece D.E., et al. Activity with thalidomide-based therapy following lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma. ASH Annu Meeting Abstr 2009, 114(22):3855.
161. Dimopoulos M.A., Kastritis E., Christoulas D., Migkou M., Gavriatopoulou M., Gkotzamanidou M., et al. Treatment of patients with relapsed/refractory multiple myeloma (MM) with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities. ASH Annu Meeting Abstr 2009, 114(22):958.
162. Sood R., Carloss H., Kerr R., Lopez J., Lee M., Druck M., et al. Retreatment with bortezomib alone or in combination for patients with multiple myeloma following an initial response to bortezomib. Am J Hematol 2009, 84(10):657-660.
163. Mateos M.V., Richardson P.G., Schlag R., Khuageva N.K., Dimopoulos M.A., Shpilberg O., et al. Bortezomib plus melphalan-prednisone continues to demonstrate a survival benefit vs melphalan-prednisone in the phase III VISTA trial in previously untreated multiple myeloma after 3 years' follow-up and extensive subsequent therapy use. ASH Annu Meeting Abstr 2009, 114(22):3859.
164. Kumar S., Blade J., Crowley J., Goldschmidt H., Hoering A., Jagannath S., et al. Natural history of multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. ASH Annu Meeting Abstr 2009, 114(22):2878.
165. Barlogie B., Velasquez W.S., Alexanian R., Cabanillas F. Etoposide, dexamethasone, cytarabine, and cisplatin in vincristine, doxorubicin, and dexamethasone-refractory myeloma. J Clin Oncol 1989, 7(10):1514-1517.
166. Lazzarino M., Corso A., Barbarano L., Alessandrino E.P., Cairoli R., Pinotti G., et al. DCEP (dexamethasone, cyclophosphamide, etoposide, and cisplatin) is an effective regimen for peripheral blood stem cell collection in multiple myeloma. Bone Marrow Transplant 2001, 28(9):835-839.
167. Lokhorst H.M., Schattenberg A., Cornelissen J.J., Thomas L.L., Verdonck L.F. Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. Blood 1997, 90(10):4206-4211.
168. Salama M., Nevill T., Marcellus D., Parker P., Johnson M., Kirk A., et al. Donor leukocyte infusions for multiple myeloma. Bone Marrow Transplant 2000, 26(11):1179-1184.
169. Lokhorst H.M., Schattenberg A., Cornelissen J.J., van Oers M.H., Fibbe W., Russell I., et al. Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome. J Clin Oncol 2000, 18(16):3031-3037.
170. Tricot G., Vesole D.H., Jagannath S., Hilton J., Munshi N., Barlogie B. Graft-versus-myeloma effect: proof of principle. Blood 1996, 87(3):1196-1198.
171. Ayuk F., Shimoni A., Nagler A., Schwerdtfeger R., Kiehl M., Sayer H.G., et al. Efficacy and toxicity of low-dose escalating donor lymphocyte infusion given after reduced intensity conditioning allograft for multiple myeloma. Leukemia 2004, 18(3):659-662.
172. van de Donk N.W., Kroger N., Hegenbart U., Corradini P., San Miguel J.F., Goldschmidt H., et al. Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma. Bone Marrow Transplant 2006, 37(12):1135-1141.
173. Lokhorst H.M., Wu K., Verdonck L.F., Laterveer L.L., van de Donk N.W., van Oers M.H., et al. The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma. Blood 2004, 103(11):4362-4364.
174. Lioznov M., El-Cheikh J., Hoffmann F., Hildebrandt Y., Ayuk F., Wolschke C., et al. Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44(+)) and T (HLA-DR(+)) cells. Bone Marrow Transplant 2010, 45(2):349-353.
175. Minnema M.C., van d V., Aarts T., Emmelot M., Mutis T., Lokhorst H.M. Lenalidomide alone or in combination with dexamethasone is highly effective in patients with relapsed multiple myeloma following allogeneic stem cell transplantation and increases the frequency of CD4+Foxp3+T cells. Leukemia 2009, 23(3):605-607.
176. Mohty M., Attal M., Marit G., Bulabois C.E., Garban F., Gratecos N., et al. Thalidomide salvage therapy following allogeneic stem cell transplantation for multiple myeloma: a retrospective study from the Intergroupe Francophone du Myelome (IFM) and the Societe Francaise de Greffe de Moelle et Therapie Cellulaire (SFGM-TC). Bone Marrow Transplant 2005, 35(2):165-169.
177. van de Donk N.W., Kroger N., Hegenbart U., Corradini P., San Miguel J.F., Goldschmidt H., et al. Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma. Blood 2006, 107(8):3415-3416.
178. Kroger N., Shimoni A., Zagrivnaja M., Ayuk F., Lioznov M., Schieder H., et al. Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma. Blood 2004, 104(10):3361-3363.
179. Bruno B., Patriarca F., Sorasio R., Mattei D., Montefusco V., Peccatori J., et al. Bortezomib with or without dexamethasone in relapsed multiple myeloma following allogeneic hematopoietic cell transplantation. Haematologica 2006, 91(6):837-839.
180. Varettoni M., Corso A., Pica G., Mangiacavalli S., Pascutto C., Lazzarino M. Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. Ann Oncol 2010, 21(2):325-330.
181. Rosinol L., Cibeira M.T., Blade J., Esteve J., Aymerich M., Rozman M., et al. Extramedullary multiple myeloma escapes the effect of thalidomide. Haematologica 2004, 89(7):832-836.
182. Zeiser R., Deschler B., Bertz H., Finke J., Engelhardt M. Extramedullary vs medullary relapse after autologous or allogeneic hematopoietic stem cell transplantation (HSCT) in multiple myeloma (MM) and its correlation to clinical outcome. Bone Marrow Transplant 2004, 34(12):1057-1065.
183. Perez-Simon J.A., Sureda A., Fernandez-Aviles F., Sampol A., Cabrera J.R., Caballero D., et al. Reduced-intensity conditioning allogeneic transplantation is associated with a high incidence of extramedullary relapses in multiple myeloma patients. Leukemia 2006, 20(3):542-545.
184. Minnema M.C., van de Donk N.W., Zweegman S., Hegenbart U., Schonland S., Raymakers R., et al. Extramedullary relapses after allogeneic non-myeloablative stem cell transplantation in multiple myeloma patients do not negatively affect treatment outcome. Bone Marrow Transplant 2008, 41(9):779-784.
185. Alegre A., Granda A., Martinez-Chamorro C., az-Mediavilla J., Martinez R., Garcia-Larana J., et al. Different patterns of relapse after autologous peripheral blood stem cell transplantation in multiple myeloma: clinical results of 280 cases from the Spanish registry. Haematologica 2002, 87(6):609-614.
186. Blade J., Perales M., Rosinol L., Tuset M., Montoto S., Esteve J., et al. Thalidomide in multiple myeloma: lack of response of soft-tissue plasmacytomas. Br J Haematol 2001, 113(2):422-424.
187. Myers B., Grimley C., Crouch D., Dolan G. Lack of response to thalidomide in plasmacytomas. Br J Haematol 2001, 115(1):234.
188. Laura R., Cibeira M.T., Uriburu C., Yantorno S., Salamero O., Blade J., et al. Bortezomib: an effective agent in extramedullary disease in multiple myeloma. Eur J Haematol 2006, 76(5):405-408.
189. Patriarca F., Prosdocimo S., Tomadini V., Vasciaveo A., Bruno B., Fanin R. Efficacy of bortezomib therapy for extramedullary relapse of myeloma after autologous and non-myeloablative allogeneic transplantation. Haematologica 2005, 90(2):278-279.
190. Biagi J.J., Prince H.M. Thalidomide is effective for extramedullary relapse of multiple myeloma post-allogeneic bone marrow transplantation. Br J Haematol 2001, 115(2):484-485.
191. Dimopoulos M.A., Kastritis E., Rosinol L., Blade J., Ludwig H. Pathogenesis and treatment of renal failure in multiple myeloma. Leukemia 2008, 22(8):1485-1493.
192. Chanan-Khan A.A., Kaufman J.L., Mehta J., Richardson P.G., Miller K.C., Lonial S., et al. Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. Blood 2007, 109(6):2604-2606.
193. San-Miguel J.F., Richardson P.G., Sonneveld P., Schuster M.W., Irwin D., Stadtmauer E.A., et al. Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study. Leukemia 2008, 22(4):842-849.
194. Ludwig H., Drach J., Graf H., Lang A., Meran J.G. Reversal of acute renal failure by bortezomib-based chemotherapy in patients with multiple myeloma. Haematologica 2007, 92(10):1411-1414.
195. Jagannath S., Barlogie B., Berenson J.R., Singhal S., Alexanian R., Srkalovic G., et al. Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impaired renal function. Cancer 2005, 103(6):1195-1200.
196. Roussou M., Kastritis E., Christoulas D., Migkou M., Gavriatopoulou M., Matsouka C., et al. Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents. ASH Annu Meeting Abstr 2009, 114(22):955.
197. Tosi P., Zamagni E., Cellini C., Cangini D., Tacchetti P., Tura S., et al. Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure. Eur J Haematol 2004, 73(2):98-103.
198. Niesvizky R., Naib T., Christos P.J., Jayabalan D., Furst J.R., Jalbrzikowski J., et al. Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naive patients undergoing front-line lenalidomide and dexamethasone therapy. Br J Haematol 2007, 138(5):640-643.
199. Roig M., Ibanez A., Garcia I., Juan A., Aguilar C., del Campo R., et al. Activity and safety of lenalidomide and dexamethasone in multiple myeloma patients with advanced renal failure: a Spanish multicenter retrospective study. ASH Annu Meeting Abstr 2009, 114(22):1886.
200. Osman K., Comenzo R., Rajkumar S.V. Deep venous thrombosis and thalidomide therapy for multiple myeloma. N Engl J Med 2001, 344(25):1951-1952.
201. Bennett C.L., Angelotta C., Yarnold P.R., Evens A.M., Zonder J.A., Raisch D.W., et al. Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer. JAMA 2006, 296(21):2558-2560.
202. Urbauer E., Kaufmann H., Nosslinger T., Raderer M., Drach J. Thromboembolic events during treatment with thalidomide. Blood 2002, 99(11):4247-4248.
203. Rajkumar S.V. Thalidomide therapy and deep venous thrombosis in multiple myeloma. Mayo Clin Proc 2005, 80(12):1549-1551.
204. Zangari M., Siegel E., Barlogie B., Anaissie E., Saghafifar F., Fassas A., et al. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood 2002, 100(4):1168-1171.
205. Zangari M., Anaissie E., Barlogie B., Badros A., Desikan R., Gopal A.V., et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 2001, 98(5):1614-1615.
206. Zonder J.A., Barlogie B., Durie B.G., McCoy J., Crowley J., Hussein M.A. Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis. Blood 2006, 108(1):403.
207. Rajkumar S.V., Jacobus S., Callander N.S., Fonseca R., Vesole D.H., Williams M.E., et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 2010, 11(1):29-37.
208. Knight R., DeLap R.J., Zeldis J.B. Lenalidomide and venous thrombosis in multiple myeloma. N Engl J Med 2006, 354(19):2079-2080.
209. Zangari M., Tricot G., Polavaram L., Zhan F., Finlayson A., Knight R., et al. Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high-dose dexamethasone. J Clin Oncol 2010, 28(1):132-135.
210. Rajkumar S.V., Hayman S.R., Lacy M.Q., Dispenzieri A., Geyer S.M., Kabat B., et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 2005, 106(13):4050-4053.
211. Klein U., Kosely F., Hillengass J., Hundemer M., Schmitt S., Neben K., et al. Effective prophylaxis of thromboembolic complications with low molecular weight heparin in relapsed multiple myeloma patients treated with lenalidomide and dexamethasone. Ann Hematol 2009, 88(1):67-71.
212. Mileshkin L., Stark R., Day B., Seymour J.F., Zeldis J.B., Prince H.M. Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring. J Clin Oncol 2006, 24(27):4507-4514.
213. Richardson P.G., Briemberg H., Jagannath S., Wen P.Y., Barlogie B., Berenson J., et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 2006, 24(19):3113-3120.
214. Mateos M.V., Oriol A., Martinez J., Cibeira M.T., de Paz R., Terol M.J., et al. Bortezomib (velcade)-melphalan-prednisone (VMP) versus velcade-thalidomide-prednisone (VTP) in elderly untreated multiple myeloma patients: which is the best partner for velcade: an alkylating or an immunomodulator agent?. ASH Annu Meeting Abstr 2008, 112(11):651.
215. Palumbo A., Bringhen S., Rossi D., Berretta S., Montefusco V., Peccatori J., et al. A phase III study of VMPT versus VMP in newly diagnosed elderly myeloma patients. J Clin Oncol 2009, 27(15s):8515.
216. Richardson P.G., Sonneveld P., Schuster M.W., Stadtmauer E.A., Facon T., Harousseau J.L., et al. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. Br J Haematol 2009, 144(6):895-903.
217. Miguel J.F.S., Dimopoulos M., Weber D., Olesnyckyj M., Yu Z., Zeldis J., et al. Dexamethasone dose adjustments seem to result in better efficacy and improved tolerability in patients with relapsed/refractory multiple myeloma who are treated with lenalidomide/dexamethasone (MM009/010 sub-analysis). ASH Annu Meeting Abstr 2007, 110(11):2712.
218. Kastritis E., Zervas K., Symeonidis A., Terpos E., Delimbassi S., Anagnostopoulos N., et al. Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG). Leukemia 2009, 23(6):1152-1157.
219. Reece D., Song K.W., Fu T., Roland B., Chang H., Horsman D.E., et al. Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13. Blood 2009, 114(3):522-525.
220. Jagannath S., Richardson P.G., Sonneveld P., Schuster M.W., Irwin D., Stadtmauer E.A., et al. Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia 2007, 21(1):151-157.
221. Sagaster V., Ludwig H., Kaufmann H., Odelga V., Zojer N., Ackermann J., et al. Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion. Leukemia 2007, 21(1):164-168.
222. Chang H., Trieu Y., Qi X., Xu W., Stewart K.A., Reece D. Bortezomib therapy response is independent of cytogenetic abnormalities in relapsed/refractory multiple myeloma. Leuk Res 2007, 31(6):779-782.
223. Richardson P.G., Barlogie B., Berenson J., Singhal S., Jagannath S., Irwin D., et al. Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma. Blood 2005, 106(9):2977-2981.
224. Chang H., Trieu Y., Qi C., Xu W., Reece D.E. Impact of cytogenetic abnormalities on outcome among patients with relapsed/refractory multiple myeloma treated with bortezomib: adverse effect of 1q21 (CKS1B) amplification. ASH Annu Meeting Abstr 2009, 114(22):2826.
225. Schilling G., Hansen T., Shimoni A., Zabelina T., Perez-Simon J.A., Gutierrez N.C., et al. Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma. Leukemia 2008, 22(6):1250-1255.